Published in J Neurol on April 01, 1999
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology (2008) 8.65
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol (2013) 0.83
Cortisol awakening response is linked to disease course and progression in multiple sclerosis. PLoS One (2013) 0.77
Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet (2000) 3.92
Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry (2008) 3.85
Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry (2008) 3.68
Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet (1998) 3.42
Differential signal transduction by five splice variants of the PACAP receptor. Nature (1993) 3.38
Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci (1999) 2.76
Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol (2000) 2.73
Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 2.45
Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology (2000) 2.34
Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol (1997) 2.16
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry (2000) 2.14
Brain activation and hypothalamic functional connectivity during human non-rapid eye movement sleep: an EEG/fMRI study. Brain (2005) 2.07
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci (2000) 2.06
Low lumbar bone mineral density in patients with major depression. Am J Psychiatry (1994) 2.05
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res (1995) 1.94
The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry (2002) 1.90
Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res (2000) 1.89
Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology (2001) 1.83
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun (1995) 1.80
Diurnal variations in the human host response to endotoxin. J Infect Dis (1996) 1.71
The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol (1999) 1.66
SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry (2004) 1.60
Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol (2000) 1.51
Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? Mol Psychiatry (2002) 1.49
Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry (1995) 1.49
The Munich vulnerability study on affective disorders: premorbid psychometric profile of affected individuals. Acta Psychiatr Scand (2004) 1.46
Restless legs syndrome. J Neurol Neurosurg Psychiatry (2001) 1.44
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun (2008) 1.43
Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry (1999) 1.42
Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience (1998) 1.42
Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol (2002) 1.41
Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev (2004) 1.41
[Core symptoms of depression. Effectiveness of antidepressant therapy]. Nervenarzt (2009) 1.40
V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci (1995) 1.39
Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry (1998) 1.38
Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep (2000) 1.37
Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Psychopharmacology (Berl) (1995) 1.35
Behavioural performance in three substrains of mouse strain 129. Brain Res (1997) 1.33
Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur J Neurosci (1993) 1.31
Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res (2001) 1.31
"Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol (2005) 1.31
Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep (2000) 1.30
Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrinology (2007) 1.29
Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol (1993) 1.28
Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry (1999) 1.28
The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience (1994) 1.28
Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol (2000) 1.26
Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry (2003) 1.24
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology (1997) 1.23
Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol (1997) 1.23
Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci (2001) 1.22
Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Mol Psychiatry (2008) 1.20
The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett (2001) 1.20
Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry (2005) 1.19
Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol (2001) 1.19
Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology (2002) 1.18
Progesterone receptor-mediated effects of neuroactive steroids. Neuron (1993) 1.18
Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci (1995) 1.16
Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations. J Inherit Metab Dis (2006) 1.15
Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav (2013) 1.15
Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry (2008) 1.15
Placental glucose transporter expression is regulated by glucocorticoids. J Clin Endocrinol Metab (1999) 1.13
Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry (1999) 1.12
Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med (1984) 1.12
Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology (1998) 1.12
Depression, comorbidities and the TNF-alpha system. Eur Psychiatry (2008) 1.12
HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology (2008) 1.12
Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am J Physiol (1996) 1.11
Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats. J Clin Invest (1994) 1.11
Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry (1996) 1.10
Neuropeptide S receptor gene -- converging evidence for a role in panic disorder. Mol Psychiatry (2010) 1.09
Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J (2000) 1.09
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology (2000) 1.09
Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol (1996) 1.09
Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept (1995) 1.08
Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology (1993) 1.08
Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog Neurobiol (1994) 1.08
Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry (1987) 1.08
Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology (1998) 1.07
Dizziness in an older community dwelling population: a multifactorial syndrome. J Nutr Health Aging (2009) 1.07
Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol (1999) 1.07
Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand (1994) 1.07
Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys J (2003) 1.06
Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J (1995) 1.06
A novel chronic social stress paradigm in female mice. Horm Behav (2010) 1.06
Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport (2000) 1.06
Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res (1998) 1.06
A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology (1999) 1.05
Cortisol, ACTH, and cardiovascular response to a cognitive challenge paradigm in aging and depression. Am J Physiol (1995) 1.05
Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol (1993) 1.05
Forced swimming evokes a biphasic response in CREB phosphorylation in extrahypothalamic limbic and neocortical brain structures in the rat. Eur J Neurosci (2002) 1.05
Genome-wide association analysis of copy number variation in recurrent depressive disorder. Mol Psychiatry (2011) 1.05
Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry (2007) 1.05